Systemic Effects by Intrathecal Administration of Triamcinolone Acetonide in Patients With Multiple Sclerosis.
blood brain-barrier
cortisol
intrathecal administration
multiple sclerosis
systemic effects
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
04
2020
accepted:
14
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
20
5
2021
Statut:
epublish
Résumé
In patients suffering from multiple sclerosis (MS), intrathecal injection of triamcinolone acetonide (TCA) has been shown to improve symptoms of spasticity. Although repeated intrathecal injection of TCA has been used in a number of studies in late-stage MS patients with spinal cord involvement, no clinical-chemical data are available on the distribution of TCA in cerebrospinal fluid (CSF) or serum. Moreover, the effects of intrathecal TCA administration on the concentrations of endogenous steroids remain poorly understood. Therefore, we have quantified TCA and selected endogenous steroids in CSF and serum of TCA-treated MS patients suffering from spasticity. Concentrations of steroids were quantified by LC-MS, ELISA, or ECLIA and compared with the blood-brain barrier status, diagnosed with the Reibergram. The concentration of TCA in CSF significantly increased during each treatment cycle up to >5 μg/ml both in male and female patients (
Identifiants
pubmed: 32982971
doi: 10.3389/fendo.2020.00574
pmc: PMC7481359
doi:
Substances chimiques
Testosterone
3XMK78S47O
Estradiol
4TI98Z838E
Triamcinolone Acetonide
F446C597KA
Corticosterone
W980KJ009P
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
574Informations de copyright
Copyright © 2020 Hoeflich, Fitzner, Walz, Hecker, Tuchscherer, Bastian, Brenmoehl, Schröder, Willenberg, Reincke and Zettl.
Références
BMC Neurol. 2004 Nov 07;4(1):18
pubmed: 15530171
Dtsch Med Wochenschr. 1978 Sep 1;103(35):1368-70
pubmed: 581070
Diabetologia. 1981 Mar;20(Suppl 1):246-254
pubmed: 27942809
Neural Regen Res. 2015 Mar;10(3):377-9
pubmed: 25878582
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
CNS Neurosci Ther. 2016 Jan;22(1):74-9
pubmed: 26584946
Cell Death Dis. 2018 Oct 17;9(11):1061
pubmed: 30333477
J Cell Biol. 2006 Apr 10;173(1):47-58
pubmed: 16585268
J Clin Diagn Res. 2017 Jun;11(6):OR01-OR02
pubmed: 28764237
Br Med J. 1959 Jun 20;1(5137):1586-7
pubmed: 13662625
Curr Pharm Des. 2012;18(29):4564-9
pubmed: 22612755
Clin Neuropharmacol. 2006 Sep-Oct;29(5):286-91
pubmed: 16960474
Autoimmun Rev. 2012 Jan;11(3):167-73
pubmed: 21619943
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Curr Treat Options Neurol. 2016 Jun;18(6):27
pubmed: 27089873
Mol Diagn Ther. 2014 Dec;18(6):631-7
pubmed: 24986188
J Neural Transm (Vienna). 2015 Jun;122(6):841-8
pubmed: 25209051
J Neurol Sci. 2003 Jul 15;211(1-2):81-4
pubmed: 12767502
Nat Rev Neurol. 2010 Mar;6(3):156-66
pubmed: 20157307
Cell Rep. 2015 Mar 24;10(11):1887-98
pubmed: 25801027
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Dec 15;1007:132-9
pubmed: 26600283
Mol Cell Endocrinol. 1998 Mar 16;138(1-2):11-23
pubmed: 9685211
Front Pharmacol. 2018 Apr 11;9:354
pubmed: 29695968
Lancet Neurol. 2014 Jul;13(7):700-9
pubmed: 24852507
Endocrinology. 2001 Jun;142(6):2686-94
pubmed: 11356720
J Clin Endocrinol Metab. 2002 Feb;87(2):589-98
pubmed: 11836290
Autoimmun Rev. 2017 Sep;16(9):925-936
pubmed: 28698092
Mol Pharmacol. 2017 Jul;92(1):12-21
pubmed: 28396564
Spinal Cord. 2015 Feb;53(2):109-13
pubmed: 25224601
Clin Chim Acta. 1987 Mar 30;163(3):319-28
pubmed: 3581475
Ther Adv Neurol Disord. 2009 Nov;2(6):42-9
pubmed: 21180629
J Pharm Pharmacol. 2005 Sep;57(9):1159-67
pubmed: 16105236
Eur J Neurol. 2006 Jan;13(1):72-6
pubmed: 16420395
J Clin Invest. 1979 Jul;64(1):145-54
pubmed: 447850